<html>
<head>PUBMED IDs for FAM83B</head>
<body bgcolor='#C5F0F2'><h1>FAM83B</h1><a href='https://pubmed.ncbi.nlm.nih.gov/22886302/'>FAM83B mediates EGFR- and RAS-driven oncogenic transformation.</a> December 10  2012<br><a href='https://pubmed.ncbi.nlm.nih.gov/22886282/'>Association of BMPR1A polymorphism, but not BMP4, with kidney size in full-term newborns.</a> July 28  2012<br><a href='https://pubmed.ncbi.nlm.nih.gov/23676467/'>FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to promote epithelial cell transformation and resistance to targeted therapies.</a> February 8  2013<br><a href='https://pubmed.ncbi.nlm.nih.gov/23912460/'>Hyperactivation of EGFR and downstream effector phospholipase D1 by oncogenic FAM83B.</a> September 5  2013<br><a href='https://pubmed.ncbi.nlm.nih.gov/25586059/'>FAM83B is a novel biomarker for diagnosis and prognosis of lung squamous cell carcinoma.</a> September 24  2015<br></body></html>
